Clinic
University of Texas Southwestern Medical Center at Dallas
University of Texas Southwestern Medical Center at Dallas was paid $6.91M by Medicaid between Jan 2019 and Dec 2024, across 201 billing codes. Its largest line is 77300, — 11% of everything it billed.
33Billing provider infoUNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
DALLAS, TX 75390
DALLAS, TX 75390
33aNPI1285798918assigned 12/20/2006
33bProvider typeClinic/Center
28Total paid$6.91M
24GClaims223,227
24DCodes billed201
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Texas
Rank by total paid#7 of 176
Median peer was paid$26K
This provider vs. median262×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MEYER, MARK controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 419 | $2K | |
| 2020 | 4,799 | $124K | |
| 2021 | 53,573 | $1.33M | |
| 2022 | 64,832 | $2.06M | |
| 2023 | 62,294 | $2.41M | |
| 2024incomplete | 37,310 | $991K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 77300 | 11% | 1,177 | 496 | $753K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.3% | 2,464 | 2,266 | $570K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 2,135 | 1,934 | $552K |
| G0378 | Hospital observation service, per hour | 6.1% | 1,401 | 717 | $424K |
| J0475 | Injection, baclofen, 10 mg | 5.6% | 746 | 728 | $384K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 1,252 | 1,196 | $331K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.9% | 4,347 | 3,856 | $270K |
| 77334 | 3.8% | 535 | 384 | $263K | |
| 77386 | 2.4% | 294 | 28 | $165K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2.2% | 409 | 394 | $149K |
| 86832 | 2.1% | 544 | 508 | $144K | |
| 86833 | 2.1% | 544 | 507 | $144K |
189 more codes
| 80053 | Comprehensive metabolic panel | 1.6% | 14,979 | $113K |
| 77301 | 1.6% | 100 | $109K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 1,827 | $98K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1.4% | 75 | $97K |
| 83880 | 1.4% | 3,043 | $96K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 17,512 | $93K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 1,221 | $88K |
| 77338 | 1.2% | 138 | $85K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 922 | $83K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,473 | $74K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,498 | $68K |
| CP007 | <1% | 1,594 | $68K | |
| 62370 | <1% | 743 | $66K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 258 | $60K |
| 86849 | <1% | 566 | $55K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,865 | $55K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,248 | $54K |
| 71250 | <1% | 726 | $53K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 455 | $53K |
| 87497 | <1% | 1,090 | $53K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,340 | $51K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 371 | $47K |
| 80197 | <1% | 3,477 | $44K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 412 | $43K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 395 | $40K |
| 80050 | General health panel | <1% | 375 | $35K |
| 84484 | <1% | 2,668 | $35K | |
| 83735 | <1% | 6,700 | $34K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 225 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,966 | $33K |
| 94010 | <1% | 602 | $32K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 512 | $30K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 266 | $30K |
| 99283 | Emergency room visit (moderate) | <1% | 1,056 | $28K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,967 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,619 | $25K |
| 86850 | <1% | 1,609 | $21K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 142 | $20K |
| 94729 | <1% | 524 | $19K | |
| 80061 | Lipid panel | <1% | 2,210 | $19K |
| 84100 | <1% | 5,179 | $18K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 317 | $18K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,742 | $17K |
| 94726 | <1% | 125 | $17K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 560 | $17K |
| 87799 | <1% | 852 | $16K | |
| 73630 | <1% | 693 | $15K | |
| 86352 | <1% | 112 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,259 | $13K |
| 96415 | <1% | 180 | $13K | |
| 81025 | <1% | 1,516 | $13K | |
| 83690 | <1% | 1,986 | $13K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,310 | $12K |
| 82248 | <1% | 2,160 | $12K | |
| 85610 | <1% | 3,002 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 190 | $12K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,699 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,080 | $11K |
| 73030 | <1% | 421 | $11K | |
| 83970 | <1% | 667 | $11K | |
| 83615 | <1% | 2,520 | $10K | |
| 87631 | <1% | 67 | $10K | |
| 83605 | <1% | 949 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 69 | $10K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 87 | $10K |
| 82728 | <1% | 1,342 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,250 | $9K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 170 | $8K |
| 87088 | <1% | 1,823 | $8K | |
| 81001 | <1% | 4,015 | $8K | |
| 85027 | <1% | 2,372 | $7K | |
| 86140 | <1% | 1,734 | $7K | |
| 84439 | <1% | 1,274 | $6K | |
| 97162 | <1% | 177 | $6K | |
| 64643 | <1% | 43 | $6K | |
| 87186 | <1% | 838 | $6K | |
| 87077 | <1% | 929 | $6K | |
| 84153 | <1% | 475 | $6K | |
| 96417 | <1% | 33 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,716 | $5K |
| 82550 | <1% | 841 | $5K | |
| 94618 | <1% | 54 | $5K | |
| 82784 | <1% | 648 | $5K | |
| 99152 | <1% | 209 | $5K | |
| 83550 | <1% | 906 | $5K | |
| 87340 | <1% | 647 | $4K | |
| 73610 | <1% | 179 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 157 | $4K |
| 94060 | <1% | 59 | $4K | |
| 64644 | <1% | 119 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 41 | $4K |
| 82607 | <1% | 564 | $4K | |
| 83540 | <1% | 989 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,085 | $4K |
| 95874 | <1% | 271 | $4K | |
| 85730 | <1% | 958 | $4K | |
| 87040 | <1% | 291 | $3K | |
| 93971 | <1% | 46 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $3K |
| 96367 | <1% | 19 | $3K | |
| 87070 | <1% | 555 | $3K | |
| 73562 | <1% | 56 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,024 | $3K |
| 84550 | <1% | 1,234 | $3K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,619 | $3K |
| 82803 | <1% | 101 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,853 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 18 | $3K |
| 86900 | <1% | 1,648 | $3K | |
| 86901 | <1% | 1,646 | $3K | |
| 86704 | <1% | 291 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 82 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,982 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 23 | $2K |
| 82043 | <1% | 1,521 | $2K | |
| 77336 | <1% | 169 | $2K | |
| 36591 | <1% | 76 | $2K | |
| 84156 | <1% | 1,727 | $2K | |
| 81003 | <1% | 811 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,224 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 104 | $2K |
| 82375 | <1% | 131 | $2K | |
| 81002 | <1% | 197 | $2K | |
| 82570 | <1% | 690 | $2K | |
| 82565 | <1% | 602 | $2K | |
| 86803 | <1% | 110 | $2K | |
| 73502 | <1% | 27 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 15 | $1K |
| 73130 | <1% | 41 | $1K | |
| 86706 | <1% | 125 | $1K | |
| 73560 | <1% | 18 | $1K | |
| 83883 | <1% | 194 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,056 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 581 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,704 | $1K |
| 82105 | <1% | 69 | $1K | |
| 80076 | <1% | 240 | $1K | |
| 82533 | <1% | 58 | $1K | |
| 84165 | <1% | 241 | $914.46 | |
| 88307 | <1% | 13 | $892.95 | |
| 85652 | <1% | 659 | $835.24 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 398 | $772.72 |
| 85045 | <1% | 255 | $746.66 | |
| 82024 | <1% | 28 | $723.59 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26 | $642.62 |
| 72100 | <1% | 26 | $617.45 | |
| 88341 | <1% | 15 | $579.96 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,524 | $559.43 |
| 84480 | <1% | 38 | $553.07 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 13 | $550.81 |
| 87205 | <1% | 219 | $453.40 | |
| 88342 | <1% | 59 | $443.83 | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $391.34 |
| 96376 | <1% | 272 | $351.33 | |
| 84403 | <1% | 15 | $308.13 | |
| 84155 | <1% | 291 | $287.93 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 953 | $227.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 238 | $222.91 |
| 36416 | <1% | 21 | $221.27 | |
| 82016 | <1% | 13 | $204.30 | |
| 82128 | <1% | 13 | $171.85 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 34 | $162.15 |
| J3490 | Unclassified drugs | <1% | 124 | $153.00 |
| 85007 | <1% | 161 | $144.84 | |
| 85379 | <1% | 15 | $127.74 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 543 | $122.06 |
| 86038 | <1% | 12 | $108.79 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 336 | $96.31 |
| 82962 | <1% | 4,189 | $95.11 | |
| 88240 | <1% | 13 | $82.02 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 46 | $65.40 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 334 | $44.08 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 427 | $33.37 |
| C1769 | Guide wire | <1% | 454 | $12.45 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,022 | $8.18 |
| 83521 | <1% | 16 | $5.17 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 3,207 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 24 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 126 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 35 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 28 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 13 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 16 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 187 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 101 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 65 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEYER, MARK (CFO)
| Provider | Location | Paid |
|---|---|---|
| Presbyterian Homes Hospice INC | Roseville, MN | $5.49M |
| University of Texas Southwestern Medical Center at Dallas | Plano, TX | $3.20M |
| University of Texas Southwestern Medical Center at Dallas | Dallas, TX | $2.08M |
| Grady Memorial Hospital Corporation | Atlanta, GA | $1.69M |
| University of Texas Southwestern Medical Center at Dallas | El Paso, TX | $40K |
| PHS Maranatha INC. | Brooklyn Center, MN | $30K |
| University of Texas Southwestern Medical Center at Dallas | Dallas, TX | $30K |
| Grandview Christian Home | Cambridge, MN | $16K |
| University of Texas Southwestern Medical Center at Dallas | Fort Worth, TX | $10K |
| University of Texas Southwestern Medical Center at Dallas | Dallas, TX | $5K |
| University of Texas Southwestern Medical Center at Dallas | Dallas, TX | $2K |
| CG Care Center, LLC. | Cottage Grove, MN | $2K |
| Vssa Care Center LLC | Oak Park Heights, MN | $958.06 |
| Presbyterian Homes of Arden Hills INC | Arden Hills, MN | $0.00 |
| Bvm-Phs Senior Housing INC | Dubuque, IA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.